18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

May 15, 2027

Study Completion Date

November 1, 2028

Conditions
Breast Cancer FemaleLobular Breast CarcinomaPET/MRIAxillary LymphadenopathyLuminal a Breast Cancer
Interventions
DRUG

FES

16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam

PROCEDURE

PET/MRI A

An additional FES PET/MRI will be performed before surgery.

PROCEDURE

PET/MRI B

Two additional PET/MRI will be performed before and after induction ET.

PROCEDURE

PET/MRI C

Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.

PROCEDURE

PET/MRI D

Two additional PET/MRI will be performed before and after two cycles of systemic therapy.

GENETIC

Translational analysis

Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.

All Listed Sponsors
collaborator

IRCCS San Raffaele

OTHER

lead

Università Vita-Salute San Raffaele

OTHER